ProtAffin AG Announces Preclinical Data in COPD for Lead Product PA401

ProtAffin AG presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona.

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona (Spain). This conference is the largest gathering of scientists and clinicians in the respiratory community in the world.

The company presents impressive efficacy data for PA401, a glycan-binding decoy protein based on human chemokine IL-8 (CXCL8) in gold-standard preclinical models of COPD. The activity of PA401 was benchmarked against other relevant treatment modalities including the PDE4 inhibitor roflumilast and the CXCR2 antagonist SCH527123. PA401 showed strong and broad anti-inflammatory activity in preclinical models, while also reducing levels of several key inflammatory biomarkers. The differentiated pharmacology of PA401 compared with other treatment